{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:27Z","timestamp":1787628087327,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018142","name":"Fuji Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04206"],"award-info":[{"award-number":["17H04206"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtct.2020.12.023","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:06:23Z","timestamp":1609423583000},"page":"241.e1-241.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan"],"prefix":"10.1016","volume":"27","author":[{"given":"Shiho","family":"Wakase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2020.12.023_bib0001","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9881","key":"10.1016\/j.jtct.2020.12.023_bib0002","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2020.12.023_bib0003","unstructured":"Surveillance Epidemiology and End Results Program. Cancer stat facts: leukemia\u2014acute lymphocytic leukemia (ALL). Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html. Accessed June 15, 2020."},{"issue":"2","key":"10.1016\/j.jtct.2020.12.023_bib0004","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtct.2020.12.023_bib0005","unstructured":"The Japan Society for Hematopoietic Cell Transplantation. Hematopoietic cell transplantation guidelines-pediatric acute lymphoblastic leukemia, third edition. Available at: https:\/\/www.jshct.com\/uploads\/files\/guideline\/03_04_all_ped03.pdf. Accessed May 15, 2020."},{"issue":"2","key":"10.1016\/j.jtct.2020.12.023_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cas.13457","article-title":"Childhood cancer incidence and survival in Japan and England: a population-based study (1993-2010)","volume":"109","author":"Nakata","year":"2018","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0007","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2020.12.023_bib0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"Moricke","year":"2010","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.jtct.2020.12.023_bib0009","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.023_bib0010","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2012. Available at: https:\/\/www.pmda.go.jp\/files\/000232773.pdf#page=10. Accessed May 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0011","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2018. Available at: https:\/\/www.pmda.go.jp\/files\/000229856.pdf. Accessed May 15, 2020."},{"issue":"9","key":"10.1016\/j.jtct.2020.12.023_bib0012","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3109\/10428194.2012.663915","article-title":"Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients","volume":"53","author":"Miano","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.jtct.2020.12.023_bib0013","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2020.12.023_bib0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","article-title":"Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia","volume":"147","author":"Locatelli","year":"2009","journal-title":"Br J Haematol"},{"issue":"36","key":"10.1016\/j.jtct.2020.12.023_bib0015","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2020.12.023_bib0016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03007995.2017.1384373","article-title":"Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"34","author":"Crotta","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0017","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.bbmt.2011.05.014","article-title":"Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"36","key":"10.1016\/j.jtct.2020.12.023_bib0018","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1200\/JCO.2006.07.1225","article-title":"Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data","volume":"24","author":"Saarinen-Pihkala","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.023_bib0019","unstructured":"Pharmaceuticals and Medical Devices Agency. New regenerative medical products approved in FY 2018. Available at: https:\/\/www.pmda.go.jp\/files\/000232655.pdf. Accessed June 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0020","unstructured":"Clinicaltrials.gov. Phase I\/IIA study of CART19 cells for patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma (Pedi CART19). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01626495. Accessed January 15, 2017."},{"key":"10.1016\/j.jtct.2020.12.023_bib0021","unstructured":"Clinicaltrials.gov. Determine efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell ALL and high risk b-cell ALL at first relapse. Determine feasibility and safety of CTL019 therapy in pediatric patients with high risk B-cell ALL that relapsed < 6 months post all-HSCT. (ELIANA). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02435849. Accessed June 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0022","unstructured":"Clinicaltrials.gov. Study of efficacy and safety of CTL019 in pediatric ALL patients. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02228096. Accessed June 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0023","unstructured":"US Food and Drug Administration. Highlights of prescribing information for KYMRIA (tisagenlecleucel). Available at: https:\/\/www.fda.gov\/downloads\/UCM573941.pdf. Accessed December 15, 2018."},{"issue":"3","key":"10.1016\/j.jtct.2020.12.023_bib0024","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.bbmt.2018.12.410","article-title":"Tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia: updated analysis of the ELIANA clinical trial","volume":"25","author":"Grupp","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/cer-2020-0069","article-title":"Tisagenlecleucel versus historical standard therapies for pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"9","author":"Ma","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"1","key":"10.1016\/j.jtct.2020.12.023_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jtct.2020.12.023_bib0027","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13427","article-title":"Cost-effectiveness of anti-CD19 chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view","volume":"105","author":"Thielen","year":"2020","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2020.12.023_bib0028","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0029","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2020.12.023_bib0030","first-page":"609","article-title":"Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States","volume":"130","author":"Hao","year":"2017","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.jtct.2020.12.023_bib0031","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.023_bib0032","unstructured":"National Institute for Health and Care Excellence. Final appraisal document for tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. Available at: https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/final-appraisal-determination-document. Accessed January 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0033","unstructured":"Canadian Agency for Drugs and Technologies in Health. Tisagenlecleucel for acute lymphoblastic leukemia: economic review report. Available at: https:\/\/cadth.ca\/sites\/default\/files\/pdf\/car-t\/op0538-tisagenlecleucel-economic-report-pALL-jan2019.pdf. Accessed October 30, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0034","unstructured":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council, version 2.0. Available at: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed February 15, 2019."},{"issue":"9","key":"10.1016\/j.jtct.2020.12.023_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9757","key":"10.1016\/j.jtct.2020.12.023_bib0036","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2020.12.023_bib0037","unstructured":"Centre for Health Technology Evaluation - National Institute for Health and Care Excellence. Exploring the assessment and appraisal ofregenerative medicines and cell therapy products. Available at: http:\/\/docplayer.net\/18693201-Exploring-the-assessment-and-appraisal-of-regenerative-medicines-and-cell-therapy-products.html. Accessed April 15, 2019."},{"issue":"4","key":"10.1016\/j.jtct.2020.12.023_bib0038","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/pbc.20922","article-title":"Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada","volume":"48","author":"MacArthur","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0039","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.023_bib0040","unstructured":"Statistics of Japan. Table 2-20: average life expectancy in Japan. Available at: http:\/\/www.stat.go.jp\/data\/nihon\/02.html. Accessed May 15, 2020."},{"issue":"5","key":"10.1016\/j.jtct.2020.12.023_bib0041","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/pbc.25451","article-title":"Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2020.12.023_bib0042","series-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","year":"2014"},{"issue":"3","key":"10.1016\/j.jtct.2020.12.023_bib0043","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.11098","article-title":"Treatment options for patients with acute myeloid leukemia with a matched sibling donor","volume":"97","author":"Sung","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2020.12.023_bib0044","unstructured":"e-Stat. Portal site of Official Statistics of Japan. Available at: https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00200573&tstat=000001084976&cycle=0&tclass1=000001085995&tclass2=000001085936&tclass3=000001085996&tclass4=000001085939. Accessed January 15, 2018."},{"issue":"9","key":"10.1016\/j.jtct.2020.12.023_bib0045","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","article-title":"Adjusting for inflation and currency changes within health economic studies","volume":"22","author":"Turner","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2020.12.023_bib0046","unstructured":"Ministry of Health, Labour and Welfare. The official gazette released on 5 Mar, 2018. Available at: http:\/\/www.mhlw.go.jp\/file.jsp?id=519684&name=file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000196319.pdf. Accessed May 15, 2020."},{"issue":"24","key":"10.1016\/j.jtct.2020.12.023_bib0047","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2020.12.023_bib0048","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2005.04.5856","article-title":"Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941","volume":"24","author":"Gaynon","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.023_bib0049","unstructured":"National Institute for Health Research. Blinatumomab for treating Philadelphia-chromosome-negative relapsed or refractory acute lymphoblastic leukaemia [ID804]. Available at: https:\/\/fundingawards.nihr.ac.uk\/award\/16\/51\/13. Accessed May 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0050","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (version 1.2017). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed February 15, 2018."},{"issue":"suppl 3","key":"10.1016\/j.jtct.2020.12.023_bib0051","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jval.2018.09.211","article-title":"PCN128 - costs of hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL): a retrospective analysis of Japanese claims data","volume":"21","author":"Wakase","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2020.12.023_bib0052","unstructured":"Japan Medical Association Research Institute. Nichiisouken working paper no.144. Available at: https:\/\/www.jmari.med.or.jp\/download\/WP144.pdf. Accessed May 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0053","unstructured":"Ministry of Health, Labour, and Welfare. Salary data in Japan (2017). Available at: http:\/\/www.mhlw.go.jp\/toukei\/itiran\/roudou\/chingin\/kouzou\/z2017\/dl\/02.pdf. Accessed May 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0054","unstructured":"The Statistics Bureau, Ministry of Internal Affairs and Communications. Historical data 1b-4 employment rate [by age group] - whole Japan, monthly data. Available at: http:\/\/www.stat.go.jp\/data\/roudou\/longtime\/03roudou.html#hyo_1. Accessed May 15, 2020."},{"key":"10.1016\/j.jtct.2020.12.023_bib0055","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Full scale introduction of cost-effectiveness evaluations in Japan. Overview (2\/20\/2019). Available at: https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf. Accessed May 15, 2020."},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0056","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0057","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2020.12.023_bib0058","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.clinthera.2017.10.017","article-title":"Cost-effectiveness of paclitaxel\u00a0+\u00a0ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in Japan","volume":"39","author":"Saito","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jtct.2020.12.023_bib0059","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2015.07.006","article-title":"Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer","volume":"90","author":"Narita","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2020.12.023_bib0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03256395","article-title":"Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer","volume":"14","author":"Shiroiwa","year":"2010","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"10.1016\/j.jtct.2020.12.023_bib0061","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/cer-2019-0065","article-title":"CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments","volume":"9","author":"Baumgardner","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2020.12.023_bib0062","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"Grupp","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.023_bib0063","series-title":"Paper presented at Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","article-title":"Quality and cost outcomes in chimeric antigen receptor T-cell immunotherapy in pediatric and young adult patients with acute lymphoblastic leukemia from the Vizient clinical database","year":"2020"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2020.12.023_bib0064","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2019-126724","article-title":"Trends in inpatient and intensive care resource utilization after chimeric antigen receptor T cell therapy for pediatric acute lymphoblastic leukemia from 2012-2019","volume":"134","author":"Myers","year":"2019","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672030097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672030097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:47Z","timestamp":1763002847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672030097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S266663672030097X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}